These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31004856)

  • 1. Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases.
    ElJalby M; Pannullo SC; Schwartz TH; Parashar B; Wernicke AG
    World Neurosurg; 2019 Jul; 127():397-404. PubMed ID: 31004856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
    Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
    J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosurgery and Immunotherapy in the Treatment of Brain Metastases.
    Ramakrishna R; Formenti S
    World Neurosurg; 2019 Oct; 130():615-622. PubMed ID: 31581411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.
    Wegner RE; Abel S; D'Amico RS; Mehta GU; Sheehan J
    J Neurooncol; 2021 Mar; 152(1):79-87. PubMed ID: 33432380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data.
    Lehrer EJ; Peterson J; Brown PD; Sheehan JP; Quiñones-Hinojosa A; Zaorsky NG; Trifiletti DM
    Radiother Oncol; 2019 Jan; 130():104-112. PubMed ID: 30241791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy.
    Weingarten N; Kruser TJ; Bloch O
    Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.
    Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S
    World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 1: Principles of Combined Treatment.
    Zhang I; Formenti SC; Knisely JPS
    Oncology (Williston Park); 2018 Feb; 32(2):e28-e32. PubMed ID: 29492951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma.
    Stera S; Balermpas P; Blanck O; Wolff R; Wurster S; Baumann R; Szücs M; Loutfi-Krauss B; Wilhelm ML; Seifert V; Rades D; Rödel C; Dunst J; Hildebrandt G; Arnold A; Meissner M; Kähler KC
    Melanoma Res; 2019 Apr; 29(2):187-195. PubMed ID: 30802230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
    Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
    J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update.
    Park HS; Chiang VL; Knisely JP; Raldow AC; Yu JB
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1731-8. PubMed ID: 22050022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of stereotactic radiosurgery in the treatment of patients with metastatic brain tumors.
    Elaimy AL; Mackay AR; Lamoreaux WT; Fairbanks RK; Demakas JJ; Cooke BS; Lee CM
    World Neurosurg; 2011; 75(5-6):673-83. PubMed ID: 21704935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases.
    Li YD; Lamano JB; Kaur G; Lamano JB; Veliceasa D; Biyashev D; Kruser T; Bloch O
    J Neurooncol; 2019 Jun; 143(2):337-347. PubMed ID: 30982197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis.
    Williams GJ; Hong AM; Thompson JF
    Crit Rev Oncol Hematol; 2024 Oct; 202():104462. PubMed ID: 39097248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.